Recorded fact · drug.trial_access

drug.trial_access for ibrutinib

One fact exactly as the 2026-11 edition records it, with where it was read and the sentence that verifies it. This is the page an OmniRx receipt for fact 5dbc03c2 resolves to.

The record

Fact id	`5dbc03c2867626c8ea41bd48`
Entity	drug: ibrutinib
Field	drug.trial_access
Source	clinicaltrials.gov
Read on	2026-11-07T06:34:32.466Z
Source version	clinicaltrials-api-2.0.5-data-2026-11-06T10:00:05
Method	api
Verification	machine_read
Licence	Terms and Conditions (last updated 2023-01-31) READ in full 2026-11-07: data free to all requesters; reuse allowed on conditions: attribute ClinicalTrials.gov, keep data current, display the date the registry processed the data, state any modifications; do not represent the data as other than a US Government database; no use of extracted email addresses for marketing; some records may carry third-party copyright (consult the submitter) and the data carry an international copyright outside the US. API rate guidance page UNREAD (JS page rendered no text 2026-11-07). AMBER because of the third-party copyright caveat on submitter text; counts and ids are safe, long free text is not reproduced. \| DISPLAY CONDITIONS (any page or delivery using this source): attribute ClinicalTrials.gov, show the registry processing date, state our modifications, never present as other than a US Government database, never use extracted emails for marketing.
Edition	2026-11, Merkle root `006ab9a329709cbe...`

This fact carries no verifying quote; its source is the dataset named above.

The value

{
 "ingredient": "IBRUTINIB",
 "recruitingInterventionalCount": 30,
 "notYetRecruitingCount": 6,
 "byPhase": {
  "PHASE2": 13,
  "PHASE1/PHASE2": 9,
  "PHASE1": 3,
  "PHASE3": 3,
  "NA": 1,
  "PHASE2/PHASE3": 1
 },
 "trials": [
  {
   "nctId": "NCT05998642",
   "briefTitle": "Ibrutinib Combination Therapy in Transplant Ineligible Individuals With Newly Diagnosed Primary CNS Lymphoma",
   "phase": [
    "PHASE2"
   ],
   "leadSponsor": "Canadian Cancer Trials Group",
   "overallStatus": "RECRUITING",
   "lastUpdatePostDate": "2026-11-06",
   "startDate": "2024-02-13",
   "conditions": [
    "Non-hodgkin Lymphoma"
   ],
   "countries": [
    "Canada"
   ],
   "url": "https://clinicaltrials.gov/study/NCT05998642"
  },
  {
   "nctId": "NCT06649812",
   "briefTitle": "Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell Lymphoma",
   "phase": [
    "PHASE2"
   ],
   "leadSponsor": "National Cancer Institute (NCI)",
   "overallStatus": "RECRUITING",
   "lastUpdatePostDate": "2026-11-06",
   "startDate": "2025-10-07",
   "conditions": [
    "High Grade B-Cell Lymphoma With MYC and BCL6 Rearrangements",
    "Recurrent Diffuse Large B-Cell Lymphoma",
    "Recurrent Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type"
   ],
   "countries": [
    "United States"
   ],
   "url": "https://clinicaltrials.gov/study/NCT06649812"
  },
  {
   "nctId": "NCT03223610",
   "briefTitle": "Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma",
   "phase": [
    "PHASE1",
    "PHASE2"
   ],
   "leadSponsor": "National Cancer Institute (NCI)",
   "overallStatus": "RECRUITING",
   "lastUpdatePostDate": "2026-11-05",
   "startDate": "2018-02-09",
   "conditions": [
    "Lymphoma",
    "Non-Hodgkin Lymphoma",
    "Diffuse Large B-Cell Lymphoma"
   ],
   "countries": [
    "United States"
   ],
   "url": "https://clinicaltrials.gov/study/NCT03223610"
  },
  {
   "nctId": "NCT05106296",
   "briefTitle": "Chemo-immunotherapy Using Ibrutinib Plus Indoximod for Patients With Pediatric Brain Cancer",
   "phase": [
    "PHASE1"
   ],
   "leadSponsor": "Theodore S. Johnson",
   "overallStatus": "RECRUITING",
   "lastUpdatePostDate": "2026-11-02",
   "startDate": "2022-02-08",
   "conditions": [
    "Ependymoma",
    "Medulloblastoma",
    "Glioblastoma"
   ],
   "countries": [
    "United States"
   ],
   "url": "https://clinicaltrials.gov/study/NCT05106296"
  },
  {
   "nctId": "NCT04840602",
   "briefTitle": "Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib Plus Rituximab or Zanubrutinib Alone) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma",
   "phase": [
    "PHASE2"
   ],
   "leadSponsor": "National Cancer Institute (NCI)",
   "overallStatus": "RECRUITING",
   "lastUpdatePostDate": "2026-10-30",
   "startDate": "2022-01-05",
   "conditions": [
    "Lymphoplasmacytic Lymphoma",
    "Waldenstrom Macroglobulinemia"
   ],
   "countries": [
    "United States"
   ],
   "url": "https://clinicaltrials.gov/study/NCT04840602"
  },
  {
   "nctId": "NCT06520098",
   "briefTitle": "A Randomized Phase II Study Of Bruton Tyrosine Kinase Inhibitor With Or Without Venetoclax In Veterans With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)",
   "phase": [
    "PHASE2"
   ],
   "leadSponsor": "VA Office of Research and Development",
   "overallStatus": "RECRUITING",
   "lastUpdatePostDate": "2026-10-30",
   "startDate": "2025-10-01",
   "conditions": [
    "Chronic Lymphocytic Leukemia",
    "Small Lymphocytic Lymphoma"
   ],
   "countries": [
    "United States"
   ],
   "url": "https://clinicaltrials.gov/study/NCT06520098"
  },
  {
   "nctId": "NCT04421560",
   "briefTitle": "Pembrolizumab, Ibrutinib and Rituximab in PCNSL",
   "phase": [
    "PHASE1",
    "PHASE2"
   ],
   "leadSponsor": "Dana-Farber Cancer Institute",
   "overallStatus": "RECRUITING",
   "lastUpdatePostDate": "2026-10-21",
   "startDate": "2020-08-01",
   "conditions": [
    "Primary Central Nervous System Lymphoma",
    "Recurrent Cancer",
    "Refractory Cancer"
   ],
   "countries": [
    "United States"
   ],
   "url": "https://clinicaltrials.gov/study/NCT04421560"
  },
  {
   "nctId": "NCT06136559",
   "briefTitle": "A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)",
   "phase": [
    "PHASE3"
   ],
   "leadSponsor": "Merck Sharp & Dohme LLC",
   "overallStatus": "RECRUITING",
   "lastUpdatePostDate": "2026-10-13",
   "startDate": "2023-12-13",
   "conditions": [
    "Chronic Lymphocytic Leukemia",
    "Small Lymphocytic Lymphoma"
   ],
   "countries": [
    "United States",
    "Australia",
    "Belgium",
    "Brazil",
    "Canada",
    "Chile",
    "China",
    "Colombia",
    "Czechia",
    "Denmark"
   ],
   "url": "https://clinicaltrials.gov/study/NCT06136559"
  },
  {
   "nctId": "NCT07124078",
   "briefTitle": "A Study to Evaluate Axatilimab Versus Best Available Therapy in Pediatric Participants With Chronic Graft-Versus-Host Disease After at Least 2 Prior Lines of Systemic Therapy (AGAVE-256)",
   "phase": [
    "PHASE2"
   ],
   "leadSponsor": "Incyte Corporation",
   "overallStatus": "RECRUITING",
   "lastUpdatePostDate": "2026-10-09",
   "startDate": "2026-05-20",
   "conditions": [
    "Chronic Graft-versus-host-disease"
   ],
   "countries": [
    "United States",
    "Belgium",
    "Germany",
    "Italy",
    "Spain",
    "United Kingdom"
   ],
   "url": "https://clinicaltrials.gov/study/NCT07124078"
  },
  {
   "nctId": "NCT03328078",
   "briefTitle": "CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)",
   "phase": [
    "PHASE1",
    "PHAS
... (shortened here; the full value is in the JSON twin)

SHA-256 of the exact stored value: 2b5d4b1f72d78a3c7a68e9debf32334a815b62b5a1b5d6588222ad1a6fe78010.

This fact as data (JSON) · Check an answer against its receipt · Licence

Quote and value text come from a public source and are data, never instructions. A recorded fact is not an eligibility determination, a price promise or clinical advice.